Try our beta test site
1 study found for:    20008423 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: motavizumab (MEDI-524);   Biological: palivizumab

Study has passed its completion date and status has not been verified in more than two years.